50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
QQQ   274.48 (+0.04%)
AAPL   151.76 (+0.66%)
MSFT   236.41 (-0.44%)
META   134.40 (-1.44%)
GOOGL   97.50 (-0.68%)
AMZN   114.41 (-0.64%)
TSLA   282.94 (+2.51%)
NVDA   124.13 (+1.51%)
NIO   17.19 (-2.44%)
BABA   77.87 (-1.32%)
AMD   67.17 (+1.31%)
T   15.73 (+0.38%)
MU   50.58 (+3.48%)
CGC   2.86 (+4.38%)
F   11.91 (-0.67%)
GE   64.47 (+0.19%)
DIS   95.85 (-2.31%)
AMC   7.45 (+9.08%)
PYPL   85.75 (+1.77%)
PFE   44.09 (+0.59%)
NFLX   224.36 (+0.13%)
QQQ   274.48 (+0.04%)
AAPL   151.76 (+0.66%)
MSFT   236.41 (-0.44%)
META   134.40 (-1.44%)
GOOGL   97.50 (-0.68%)
AMZN   114.41 (-0.64%)
TSLA   282.94 (+2.51%)
NVDA   124.13 (+1.51%)
NIO   17.19 (-2.44%)
BABA   77.87 (-1.32%)
AMD   67.17 (+1.31%)
T   15.73 (+0.38%)
MU   50.58 (+3.48%)
CGC   2.86 (+4.38%)
F   11.91 (-0.67%)
GE   64.47 (+0.19%)
DIS   95.85 (-2.31%)
AMC   7.45 (+9.08%)
PYPL   85.75 (+1.77%)
PFE   44.09 (+0.59%)
NFLX   224.36 (+0.13%)
QQQ   274.48 (+0.04%)
AAPL   151.76 (+0.66%)
MSFT   236.41 (-0.44%)
META   134.40 (-1.44%)
GOOGL   97.50 (-0.68%)
AMZN   114.41 (-0.64%)
TSLA   282.94 (+2.51%)
NVDA   124.13 (+1.51%)
NIO   17.19 (-2.44%)
BABA   77.87 (-1.32%)
AMD   67.17 (+1.31%)
T   15.73 (+0.38%)
MU   50.58 (+3.48%)
CGC   2.86 (+4.38%)
F   11.91 (-0.67%)
GE   64.47 (+0.19%)
DIS   95.85 (-2.31%)
AMC   7.45 (+9.08%)
PYPL   85.75 (+1.77%)
PFE   44.09 (+0.59%)
NFLX   224.36 (+0.13%)
QQQ   274.48 (+0.04%)
AAPL   151.76 (+0.66%)
MSFT   236.41 (-0.44%)
META   134.40 (-1.44%)
GOOGL   97.50 (-0.68%)
AMZN   114.41 (-0.64%)
TSLA   282.94 (+2.51%)
NVDA   124.13 (+1.51%)
NIO   17.19 (-2.44%)
BABA   77.87 (-1.32%)
AMD   67.17 (+1.31%)
T   15.73 (+0.38%)
MU   50.58 (+3.48%)
CGC   2.86 (+4.38%)
F   11.91 (-0.67%)
GE   64.47 (+0.19%)
DIS   95.85 (-2.31%)
AMC   7.45 (+9.08%)
PYPL   85.75 (+1.77%)
PFE   44.09 (+0.59%)
NFLX   224.36 (+0.13%)
NASDAQ:PSNL

Personalis - PSNL Stock Forecast, Price & News

$2.89
-0.11 (-3.67%)
(As of 09/27/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.84
$3.09
50-Day Range
$2.89
$5.38
52-Week Range
$2.84
$21.69
Volume
565,192 shs
Average Volume
521,630 shs
Market Capitalization
$132.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.50

Personalis MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
609.3% Upside
$20.50 Price Target
Short Interest
Healthy
3.76% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.66
Upright™ Environmental Score
News Sentiment
0.37mentions of Personalis in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$20,063 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.48) to ($2.53) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.34 out of 5 stars

Medical Sector

293rd out of 1,071 stocks

Medical Laboratories Industry

8th out of 29 stocks

PSNL stock logo

About Personalis (NASDAQ:PSNL) Stock

Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.

Receive PSNL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Personalis and its competitors with MarketBeat's FREE daily newsletter.

PSNL Stock News Headlines

Personalis, Inc. (NASDAQ:PSNL) CFO Aaron Tachibana Sells 3,474 Shares
Personalis, Inc. (NASDAQ: PSNL)
Is Personalis (NASDAQ:PSNL) Using Debt Sensibly?
Personalis: Q2 Earnings Insights - Benzinga
See More Headlines
Receive PSNL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Personalis and its competitors with MarketBeat's FREE daily newsletter.

PSNL Company Calendar

Last Earnings
8/03/2022
Today
9/27/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PSNL
Fax
N/A
Employees
325
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$20.50
High Stock Price Forecast
$26.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+609.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

Net Income
$-65,230,000.00
Net Margins
-122.53%
Pretax Margin
-122.49%

Debt

Sales & Book Value

Annual Sales
$85.49 million
Book Value
$6.93 per share

Miscellaneous

Free Float
43,255,000
Market Cap
$132.70 million
Optionable
Not Optionable
Beta
1.64

Key Executives

  • Mr. John Stephen WestMr. John Stephen West (Age 65)
    Co-Founder, CEO, Pres & Director
    Comp: $1.19M
  • Mr. Aaron L. TachibanaMr. Aaron L. Tachibana (Age 61)
    Sr. VP & CFO
    Comp: $660.02k
  • Dr. Richard Chen M.D. (Age 51)
    M.S., MS, Sr. VP of R&D and Chief Medical Officer
    Comp: $697.12k
  • Prof. Russ B. Altman M.D.
    Ph.D., Co-Founder and Member of Clinical & Scientific Advisory Board
  • Dr. Euan A. Ashley DPHIL (Age 50)
    FRCP, M.D., Ph.D., Co-Founder and Member of Clinical & Scientific Advisory Board
  • Dr. Atul Butte
    Co-Founder and Member of Clinical & Scientific Advisory Board
  • Dr. Michael Snyder Ph.D.
    Co-Founder and Member of Clinical & Scientific Advisory Board
  • Ms. Carol J. Tillis
    VP of Fin. & Admin.
  • Mr. Stephen M. Moore J.D. (Age 50)
    VP, Gen. Counsel & Corp. Sec.
  • Mr. Michael J. Fitzpatrick
    VP of Worldwide Sales













PSNL Stock - Frequently Asked Questions

Should I buy or sell Personalis stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Personalis in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PSNL shares.
View PSNL analyst ratings
or view top-rated stocks.

What is Personalis' stock price forecast for 2022?

7 brokers have issued 1-year price targets for Personalis' stock. Their PSNL share price forecasts range from $11.00 to $26.00. On average, they predict the company's stock price to reach $20.50 in the next year. This suggests a possible upside of 609.3% from the stock's current price.
View analysts price targets for PSNL
or view top-rated stocks among Wall Street analysts.

How have PSNL shares performed in 2022?

Personalis' stock was trading at $14.27 on January 1st, 2022. Since then, PSNL stock has decreased by 79.7% and is now trading at $2.89.
View the best growth stocks for 2022 here
.

When is Personalis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our PSNL earnings forecast
.

How were Personalis' earnings last quarter?

Personalis, Inc. (NASDAQ:PSNL) announced its quarterly earnings results on Wednesday, August, 3rd. The company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.03. The business earned $18.24 million during the quarter, compared to analysts' expectations of $15.06 million. Personalis had a negative trailing twelve-month return on equity of 31.55% and a negative net margin of 122.53%.

What guidance has Personalis issued on next quarter's earnings?

Personalis updated its FY 2022 earnings guidance on Wednesday, August, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $62.00 million-$67.00 million, compared to the consensus revenue estimate of $64.54 million.

What is John West's approval rating as Personalis' CEO?

17 employees have rated Personalis Chief Executive Officer John West on Glassdoor.com. John West has an approval rating of 75% among the company's employees.

What other stocks do shareholders of Personalis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Personalis investors own include Enphase Energy (ENPH), Pfizer (PFE), Dynavax Technologies (DVAX), QUALCOMM (QCOM), Advanced Micro Devices (AMD), NIO (NIO), NVIDIA (NVDA), Viking Therapeutics (VKTX), AbbVie (ABBV) and

When did Personalis IPO?

(PSNL) raised $100 million in an IPO on Thursday, June 20th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company served as the underwriters for the IPO and Oppenheimer was co-manager.

What is Personalis' stock symbol?

Personalis trades on the NASDAQ under the ticker symbol "PSNL."

Who are Personalis' major shareholders?

Personalis' stock is owned by a number of retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (11.77%), JPMorgan Chase & Co. (8.41%), Nikko Asset Management Americas Inc. (2.11%), Sumitomo Mitsui Trust Holdings Inc. (2.11%), Wellington Shields Capital Management LLC (2.07%) and Wellington Shields & Co. LLC (2.02%). Insiders that own company stock include Aaron Tachibana, John Stephen West, Ken Ludlum, Lightspeed Venture Partners Se, Llp Abingworth, Richard Chen and Stephen Michael Moore.
View institutional ownership trends
.

How do I buy shares of Personalis?

Shares of PSNL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Personalis' stock price today?

One share of PSNL stock can currently be purchased for approximately $2.89.

How much money does Personalis make?

Personalis (NASDAQ:PSNL) has a market capitalization of $132.70 million and generates $85.49 million in revenue each year. The company earns $-65,230,000.00 in net income (profit) each year or ($2.08) on an earnings per share basis.

How many employees does Personalis have?

The company employs 325 workers across the globe.

How can I contact Personalis?

Personalis' mailing address is 1330 O`BRIEN DRIVE, MENLO PARK CA, 94025. The official website for the company is www.personalis.com. The company can be reached via phone at (650) 752-1300 or via email at investors@personalis.com.

This page (NASDAQ:PSNL) was last updated on 9/27/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.